NYSE:GSK - GlaxoSmithKline Stock Price, Forecast & News

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

GlaxoSmithKline declared a quarterly dividend on Friday, May 3rd. Shareholders of record on Friday, May 17th will be paid a dividend of $0.4953 per share on Thursday, July 11th. This represents a $1.98 annualized dividend and a yield of 4.14%. The ex-dividend date of this dividend is Thursday, May 16th. View GlaxoSmithKline's Dividend History.

GlaxoSmithKline plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, October, 30th. The pharmaceutical company reported $0.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.10. The pharmaceutical company earned $11.57 billion during the quarter, compared to analysts' expectations of $11.34 billion. GlaxoSmithKline had a net margin of 13.76% and a return on equity of 92.73%. View GlaxoSmithKline's Earnings History.

GlaxoSmithKline is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for GlaxoSmithKline.

12 brokers have issued 1 year price objectives for GlaxoSmithKline's stock. Their forecasts range from $45.00 to $53.00. On average, they expect GlaxoSmithKline's share price to reach $49.00 in the next year. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for GlaxoSmithKline.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GlaxoSmithKline.

News stories about GSK stock have trended negative on Tuesday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GlaxoSmithKline earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news coverage about the pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for GlaxoSmithKline.

GlaxoSmithKline saw a increase in short interest in December. As of December 13th, there was short interest totalling 7,110,000 shares, an increase of 6.0% from the November 28th total of 6,710,000 shares. Based on an average daily volume of 2,680,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 0.3% of the shares of the stock are sold short. View GlaxoSmithKline's Current Options Chain.

Some companies that are related to GlaxoSmithKline include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Eli Lilly And Co (LLY), AbbVie (ABBV), Sanofi (SNY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Bank of America (Bac), Johnson & Johnson (JNJ), Intel (INTC), General Electric (GE) and Exxon Mobil (xom).

GlaxoSmithKline's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Chemung Canal Trust Co. (0.01%), Hennessy Advisors Inc. (0.00%), Farmers Trust Co. (0.00%), Ipswich Investment Management Co. Inc. (0.00%), AE Wealth Management LLC (0.00%) and Hamilton Wealth LLC (0.00%). View Institutional Ownership Trends for GlaxoSmithKline.

GSK stock was sold by a variety of institutional investors in the last quarter, including Farmers Trust Co., Zeke Capital Advisors LLC, Hennessy Advisors Inc., Fluent Financial LLC, Mountain Capital Investment Advisors Inc, Chemung Canal Trust Co., Allred Capital Management LLC and Livingston Group Asset Management CO operating as Southport Capital Management. View Insider Buying and Selling for GlaxoSmithKline.

GSK stock was bought by a variety of institutional investors in the last quarter, including Boenning & Scattergood Inc., AE Wealth Management LLC, Curbstone Financial Management Corp, OLD National Bancorp IN, Ingalls & Snyder LLC, First Hawaiian Bank, Accurate Investment Solutions Inc. and Rockland Trust Co.. View Insider Buying and Selling for GlaxoSmithKline.

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GSK stock can currently be purchased for approximately $47.89.

GlaxoSmithKline has a market capitalization of $119.45 billion and generates $41.14 billion in revenue each year. The pharmaceutical company earns $4.84 billion in net income (profit) each year or $3.16 on an earnings per share basis. GlaxoSmithKline employs 95,490 workers across the globe.View Additional Information About GlaxoSmithKline.

The official website for GlaxoSmithKline is http://www.gsk.com/.

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]